Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03092986
Recruitment Status : Completed
First Posted : March 28, 2017
Last Update Posted : March 8, 2019
Sponsor:
Information provided by (Responsible Party):
Anshu Kumar Thakur, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Brief Summary:

Lung cancer is the leading malignancy worldwide and in Bangladesh. Most of the lung cancer is of Non-small Cell Lung Cancer (NSCLC) type. For locally advanced NSCLC, combined modality treatment is required. Concurrent chemo-radiotherapy and sequential chemo-radiotherapy are the two recommended options. Sequential chemo-radiotherapy is mainly practiced in Bangladesh due to its less toxicity profile. There is no head to head comparative study done which focuses on the sequential chemotherapy regimens used in locally advanced NSCLC.

Hypothesis:

Null Hypothesis (H0): Sequential chemotherapy with cisplatin and vinblastine followed by radiotherapy and paclitaxel and carboplatin followed by the same radiotherapy in locally advanced NSCLC, there is no difference in loco-regional tumor control.

Alternative Hypothesis (HA): Sequential chemotherapy with cisplatin and vinblastine followed by radiotherapy and paclitaxel and carboplatin followed by the same radiotherapy in locally advanced NSCLC, cisplatin and vinblastine is more responsive and effective in loco-regional tumor control than paclitaxel and carboplatin.


Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: Paclitaxel Drug: Carboplatin Drug: Cisplatin Drug: Vinblastine Sulfate Radiation: three dimensional conformal radiotherapy Phase 4

  Hide Detailed Description

Detailed Description:

Lung cancer is the leading malignancy worldwide and in Bangladesh. Most of the lung cancer is of Non-small Cell Lung Cancer (NSCLC) type. For locally advanced NSCLC, combined modality treatment is required. Concurrent chemo-radiotherapy and sequential chemo-radiotherapy are the two recommended options. Sequential chemo-radiotherapy is mainly practiced in Bangladesh due to its less toxicity profile. There is no head to head comparative study done which focuses on the sequential chemotherapy regimens used in locally advanced NSCLC.

Aim and Objective:

To compare treatment outcome and acute toxicities between two standard sequential chemotherapy regimens (Cisplatin and Vinblastine followed by radiotherapy and Paclitaxel and Carboplatin followed by same radiotherapy) in patients with locally advanced stage III NSCLC.

Material and Method:

A total number of 60 patients, who are clinically locally advanced (stage III A and III B), histologically proven NSCLC, inoperable and with ECOG performance score upto grade 2 and body weight loss <10 % in 3 months will be included in this study.

Patients will be randomly assigned to receive either Arm A or Arm B. Arm A will receive - paclitaxel 200 mg/m2 body surface area(BSA) i.v over 3 hrs on D1; carboplatin Area Under Curve(AUC) 6 i.v over 60 minutes on D1 every 3 wks for 2 cycles followed by radiotherapy with 6000 (Centigray)c Gy given in 30 fractions beginning on day 42 And Arm B will receive - cisplatin (100 mg/m2 BSA i.v over 2 hrs. on days 1 and 29) and vinblastine (5 mg/m2 BSA i.v rapidly push weekly on days 1,8,15,22 and 29) followed by radiotherapy with 6000 cGy given in 30 fractions beginning on day 50 .

All patients will be followed up as per guideline for 6 months in this study. Discussion: All the relevant data will be compiled on a master chart first and then statistical analysis of the results will be obtained by using Window based computer software devised with Statistical Packages for Social Sciences (SPSS-17) (SPSS Inc, Chicago Illinois(IL) USA). The data will be analyzed using Chi-square test and 'T' test and association will be analyzed by Pearson's correlation coefficient (r value) test. The results will be presented in tables, figures, diagrams. Significant value of 'p' will be decided at a level of 0.05 in two tailed tests.

Selection of patients:

A. Inclusion Criteria:

  • Patients with locally advanced (stage III a, b) NSCLC.
  • Patients who are inoperable. Patients Eastern Co-operative Group (ECOG) performance score up to grade 2.

B. Exclusion Criteria:

  • Age below 18 years.
  • Patients with history of prior chemotherapy or radiotherapy to lung region.
  • Serious concomitant medical illness including severe heart disease, uncontrolled diabetes mellitus or hypertension.
  • Life expectancy < 6 months.
  • Patient with uncontrolled infection
  • Pregnant or lactating woman.
  • Psychiatric illness.

Minimum laboratory criteria required to include:

  • Hemoglobin should be more than 10 gm. /dl or more than 60%.
  • An absolute white blood count(WBC) more than or equal to 4000 cells/mm3.
  • Platelet count more than or equal to 100000 cells/mm3.
  • Bilirubin level should be equal to or less than 1.5 mg/dl.
  • SGPT(serum glutamic-pyruvic transaminase) level not more than 4 times of the upper limit.
  • Serum creatinine level should be equal to or less than 1.5 mg/dl.
  • Blood Urea level less than 50 mg/dl. Sampling technique Randomized number generator, a random number generator is a computational process that produces random numbers by using statistical algorithm.

Outcome measures:

table- clinical response , a 3rd follow up at week 30 after completion of treatment for both the arms (n=60)

response Arm A Arm B X2 value P value Complete response (CR) Partial response (PR) Progressive disease (PD) Stable disease (SD)

Responses Description Complete Response ( CR ) Disappearance of all known diseases, confirmed at ≥ 4 weeks Partial Response ( PR ) ≥ 50 % decrease from baseline, confirmed at ≥ 4 weeks.

Progressive disease ( PD ) ≥ 25 % increase in one or more lesions or appearance of new lesions Stable disease ( SD ) Neither PR or PD criteria met


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized Controlled type, 60 patients randomized with help of randomized number generator in two arms, Arm A and Arm B, each with at least 30 number of patients, research material will be data collection form,Arm A will receive paclitaxel 200 mg/m2 i.v over 3 hrs on D1; carboplatin AUC 6 i.v over 60 minutes on D1 every 3 wks for 2 cycles followed by radiotherapy with 6000 c Gy given in 30 fractions beginning on day 42 , Arm B willl receive - cisplatin (100 mg/m2 BSA i.v over 2 hrs. on days 1 and 29) and vinblastine (5 mg/m2 BSA i.v rapidly push weekly on days 1,8,15,22 and 29) followed by radiotherapy with 6000 cGy given in 30 fractions beginning on day 50 ,data will be analysed and interpreted and result will be drawn on basis of outcome measures which is again based on tumor response RECIST criteria
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
Actual Study Start Date : January 1, 2017
Actual Primary Completion Date : June 1, 2018
Actual Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: chemotherapy with paclitaxel and carboplatin
Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
Drug: Paclitaxel
paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
Other Name: Xelpac

Drug: Carboplatin
carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
Other Name: carboplat

Radiation: three dimensional conformal radiotherapy
three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29

Experimental: chemotherapy with cisplatin and vinblastine
Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
Drug: Cisplatin
cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
Other Name: Platinex

Drug: Vinblastine Sulfate
Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
Other Name: Velvin

Radiation: three dimensional conformal radiotherapy
three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29




Primary Outcome Measures :
  1. tumor response [ Time Frame: 30 weeks ]

    complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD),Responses Description Complete Response ( CR ) Disappearance of all known diseases, confirmed at ≥ 4 weeks.

    Partial Response ( PR ) ≥ 50 % decrease from baseline, confirmed at ≥ 4 weeks. Progressive disease ( PD ) ≥ 25 % increase in one or more lesions or appearance of new lesions Stable disease ( SD ) Neither PR or PD criteria met final tumor response will be seen in 30 weeks of starting of completion and will be considered as the primary outcome




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Patients with locally advanced (stage III a, b) non-small cell lung cancer.

    • Patients who are inoperable. Patients Eastern Co-operative Group (ECOG) performance score up to grade 2.

Exclusion Criteria:

  • • Age below 18 years.

    • Patients with history of prior chemotherapy or radiotherapy to lung region.
    • Serious concomitant medical illness including severe heart disease, uncontrolled diabetes mellitus or hypertension.
    • Life expectancy < 6 months.
    • Patient with uncontrolled infection
    • Pregnant or lactating woman.
    • Psychiatric illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03092986


Locations
Layout table for location information
Bangladesh
Department of Oncology,Bangabandhu Sheikh Mujib Medical university
Dhaka, Bangladesh, 1000
Sponsors and Collaborators
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Layout table for additonal information
Responsible Party: Anshu Kumar Thakur, MD Oncology program Phase B Resident Doctor,Department of Oncology,Principal investigator., Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
ClinicalTrials.gov Identifier: NCT03092986     History of Changes
Other Study ID Numbers: BangabandhuONCOLOGY
First Posted: March 28, 2017    Key Record Dates
Last Update Posted: March 8, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Paclitaxel
Vinblastine
Albumin-Bound Paclitaxel
Cisplatin
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action